Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels

Infection

Volumn 36, Issue 3, 2008, Pages 266-270

  De Felipe, B ^a   Blanco, A ^b   Soriano Sarabia, N ^a   Munoz Fernandez M A ^b   Genebat, M ^a   Vallejo, A ^a   Leal, M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; MITOCHONDRIAL DNA; NEVIRAPINE; NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; RASH; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DNA, MITOCHONDRIAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 45849117184     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7312-z     Document Type: Article

References (19)

1. Palella FJ, Delaney K, Moorman A, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, for the HIV outpatient study investigators: Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. New Engl J Med 1998; 338: 853-860.
2. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5-S14.
3. Friedland GH, Williams A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13: S61-S72.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
6. Vigouroux C, Gharakanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W: Diabetes, insulin resistance and dyslipidaemias in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999; 25: 225-232.
7. Van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia A, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegyi D, Van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP, Lange JMA: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987-999.
8. Martin JL, Brown CE, Matthews-Davis N, Reardon JE: Effects of antiviral nucleoside analogs on human DNA polymerase and mitochondrial DNA syntesis. Antimicrob Agents Chemother 1994; 38: 2743-2749.
9. Johnson AA, Ray AS, Hanes JW, Suo Z, Colacino JM, Anderson KS, Johnson KA: Toxicity of nucleoside analogues and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847-50857.
10. Cossarizza A, Moyle G: Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18: 137-151.
11. Miro O, Gomez M, Pedrol E, Cardellach F, Nunes V, Casademont J: Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy. AIDS 2000; 14: 1855-1857.
12. Cote HCF, Brumme ZL, Craib KJP, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan R, O'Shaughnessy MV, Montaner LSG: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-820.
13. Negredo E,Molto J, Burger D, Cote H, Miro O, Ribalta J, Martinez E, Puig J, Ruiz L, Salazar J, Lopez S, Montaner J, Rey-Joly C, Clotet B: Lopinavir/Ritonavir plus nevirapina as a nucleoside-sparing approach in antirretroviral-experienced patients (NEKA Study). J Acquir Immune Defic Syndr 2005; 38: 47-52.
14. Vittecoq D, Jardel C, Barthélémy C, Escaut L, Cheminot N, Chapin S, Sternberg D, Maisonobe T, Lombes A: Mitochondrial damage associated with long-term antiretroviral treatment: associated or causal disorder? J Acquir Immune Defic Syndr 2002; 31: 299-308.
15. Walker UA, Setzer B, Venhoff N: Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165-2173.
16. McComsey G, Bai RK, Maa JF, Seekins D, Wong LJ: Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects. J Acquir Immune Defic Syndr 2005; 39: 181-188.
17. Nolan D, John M, Mallal S: Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir Ther 2001; 6: 145-160.
18. De la Rosa R, Ruiz-Mateos E, Rubio A, Abad MA, Vallejo A, Rivero L, Genebat M, Sánchez-Quijano A, Lissen E, Leal M: Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004; 53: 95-101.
19. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo U, van der Westhuizen I, Malan D: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363: 1253-1263.